Alicaforsen

DRUG6 trials

Sponsors

Ionis Pharmaceuticals, Inc., Atlantic Pharmaceuticals Ltd

Conditions

Crohn's DiseaseIBDPouchitisUlcerative Colitis

Phase 1

Phase 1 Food Effect Study for Alicaforsen Tablets

CompletedNCT03473626

Atlantic Pharmaceuticals LtdIBD

Start: 2018-03-16End: 2018-04-06Updated: 2018-11-07

Phase 2

ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis

CompletedNCT00063414

Ionis Pharmaceuticals, Inc.Ulcerative Colitis

Start: 2002-11-20End: 2005-03-24Updated: 2022-12-05

ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis.

CompletedNCT00063830

Ionis Pharmaceuticals, Inc.Ulcerative Colitis

Start: 2003-04-03End: 2004-10-11Updated: 2022-12-05

Phase 3

Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease

CompletedNCT00048113

Ionis Pharmaceuticals, Inc.Crohn's Disease

Start: 2001-01-10End: 2002-04-27Target: 150Updated: 2022-12-05

Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease

CompletedNCT00048295

Ionis Pharmaceuticals, Inc.Crohn's Disease

Start: 2002-05-31Target: 150Updated: 2022-08-15

Efficacy of Alicaforsen in Pouchitis Patients Who Have Failed to Respond to at Least One Course of Antibiotics

CompletedNCT02525523

Atlantic Pharmaceuticals LtdPouchitis

Start: 2015-12-03End: 2018-10-29Updated: 2020-02-25

Related Papers

P268 Development and validation of a novel composite index for the assessment of endoscopic and histologic disease activity in pouchitis: The Atlantic pouchitis index.

Journal of Crohn s and Colitis2023-01-305 citations